Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
PLoS Negl Trop Dis ; 15(11): e0009503, 2021 11.
Article in English | MEDLINE | ID: mdl-34843489

ABSTRACT

BACKGROUND: Schistosoma mansoni histone deacetylase 8 (SmHDAC8) has elicited considerable interest as a target for drug discovery. Invalidation of its transcripts by RNAi leads to impaired survival of the worms in infected mice and its inhibition causes cell apoptosis and death. To determine why it is a promising therapeutic target the study of the currently unknown cellular signaling pathways involving this enzyme is essential. Protein partners of SmHDAC8 were previously identified by yeast two-hybrid (Y2H) cDNA library screening and by mass spectrometry (MS) analysis. Among these partners we characterized SmRho1, the schistosome orthologue of human RhoA GTPase, which is involved in the regulation of the cytoskeleton. In this work, we validated the interaction between SmHDAC8 and SmRho1 and explored the role of the lysine deacetylase in cytoskeletal regulation. METHODOLOGY/PRINCIPAL FINDINGS: We characterized two isoforms of SmRho1, SmRho1.1 and SmRho1.2. Co- immunoprecipitation (Co-IP)/Mass Spectrometry (MS) analysis identified SmRho1 partner proteins and we used two heterologous expression systems (Y2H assay and Xenopus laevis oocytes) to study interactions between SmHDAC8 and SmRho1 isoforms. To confirm SmHDAC8 and SmRho1 interaction in adult worms and schistosomula, we performed Co-IP experiments and additionally demonstrated SmRho1 acetylation using a Nano LC-MS/MS approach. A major impact of SmHDAC8 in cytoskeleton organization was documented by treating adult worms and schistosomula with a selective SmHDAC8 inhibitor or using RNAi followed by confocal microscopy. CONCLUSIONS/SIGNIFICANCE: Our results suggest that SmHDAC8 is involved in cytoskeleton organization via its interaction with the SmRho1.1 isoform. The SmRho1.2 isoform failed to interact with SmHDAC8, but did specifically interact with SmDia suggesting the existence of two distinct signaling pathways regulating S. mansoni cytoskeleton organization via the two SmRho1 isoforms. A specific interaction between SmHDAC8 and the C-terminal moiety of SmRho1.1 was demonstrated, and we showed that SmRho1 is acetylated on K136. SmHDAC8 inhibition or knockdown using RNAi caused extensive disruption of schistosomula actin cytoskeleton.


Subject(s)
GTP Phosphohydrolases/chemistry , Histone Deacetylases/chemistry , Schistosoma mansoni/metabolism , rhoA GTP-Binding Protein/chemistry , Acetylation , Animals , Female , GTP Phosphohydrolases/genetics , GTP Phosphohydrolases/metabolism , Histone Deacetylases/genetics , Histone Deacetylases/metabolism , Humans , Male , Mice , Mice, Inbred BALB C , Oocytes , RNA Interference , Schistosoma mansoni/genetics , Tandem Mass Spectrometry , Xenopus laevis , rhoA GTP-Binding Protein/genetics , rhoA GTP-Binding Protein/metabolism
2.
Eur J Med Chem ; 225: 113745, 2021 Dec 05.
Article in English | MEDLINE | ID: mdl-34392190

ABSTRACT

Schistosomiasis is a major neglected parasitic disease that affects more than 265 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. In this study, we chemically optimized our previously reported benzhydroxamate-based inhibitors of Schistosoma mansoni histone deacetylase 8 (smHDAC8). Crystallographic analysis provided insights into the inhibition mode of smHDAC8 activity by the highly potent inhibitor 5o. Structure-based optimization of the novel inhibitors was carried out using the available crystal structures as well as docking studies on smHDAC8. The compounds were evaluated in screens for inhibitory activity against schistosome and human HDACs (hHDAC). The in vitro and docking results were used for detailed structure activity relationships. The synthesized compounds were further investigated for their lethality against the schistosome larval stage using a fluorescence-based assay. The most promising inhibitor 5o showed significant dose-dependent killing of the schistosome larvae and markedly impaired egg laying of adult worm pairs maintained in culture.


Subject(s)
Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Schistosomiasis/drug therapy , Animals , Crystallography, X-Ray , Dose-Response Relationship, Drug , HEK293 Cells , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylase Inhibitors/chemistry , Humans , Models, Molecular , Molecular Structure , Recombinant Proteins/metabolism , Schistosoma mansoni/enzymology , Structure-Activity Relationship
3.
PLoS Negl Trop Dis ; 14(7): e0008332, 2020 07.
Article in English | MEDLINE | ID: mdl-32609727

ABSTRACT

Treatment and control of schistosomiasis still rely on only one effective drug, praziquantel (PZQ) and, due to mass treatment, the increasing risk of selecting for schistosome strains that are resistant to PZQ has alerted investigators to the urgent need to develop novel therapeutic strategies. The histone-modifying enzymes (HMEs) represent promising targets for the development of epigenetic drugs against Schistosoma mansoni. In the present study, we targeted the S. mansoni lysine-specific demethylase 1 (SmLSD1), a transcriptional corepressor, using a novel and selective synthetic inhibitor, MC3935, which was used to treat schistosomula and adult worms in vitro. By using cell viability assays and optical and electron microscopy, we showed that treatment with MC3935 affected parasite motility, egg-laying, tegument, and cellular organelle structures, culminating in the death of schistosomula and adult worms. In silico molecular modeling and docking analysis suggested that MC3935 binds to the catalytic pocket of SmLSD1. Western blot analysis revealed that MC3935 inhibited SmLSD1 demethylation activity of H3K4me1/2. Knockdown of SmLSD1 by RNAi recapitulated MC3935 phenotypes in adult worms. RNA-Seq analysis of MC3935-treated parasites revealed significant differences in gene expression related to critical biological processes. Collectively, our findings show that SmLSD1 is a promising drug target for the treatment of schistosomiasis and strongly support the further development and in vivo testing of selective schistosome LSD1 inhibitors.


Subject(s)
Enzyme Inhibitors/pharmacology , Histone Demethylases/antagonists & inhibitors , Schistosoma mansoni/drug effects , Schistosoma mansoni/ultrastructure , Schistosomiasis mansoni/drug therapy , Animals , Anthelmintics/pharmacology , Drug Resistance , Microscopy, Electron, Scanning , Oviposition/drug effects , Praziquantel/pharmacology , Schistosomiasis mansoni/parasitology , Schistosomiasis mansoni/pathology
4.
ChemMedChem ; 15(7): 571-584, 2020 04 03.
Article in English | MEDLINE | ID: mdl-31816172

ABSTRACT

Schistosomiasis is a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma, which affects over 200 million people worldwide and leads to at least 300,000 deaths every year. In this study, initial screening revealed the triazole-based hydroxamate 2 b (N-hydroxy-1-phenyl-1H-1,2,3-triazole-4-carboxamide) exhibiting potent inhibitory activity toward the novel antiparasitic target Schistosoma mansoni histone deacetylase 8 (smHDAC8) and promising selectivity over the major human HDACs. Subsequent crystallographic studies of the 2 b/smHDAC8 complex revealed key interactions between the inhibitor and the enzyme's active site, thus explaining the unique selectivity profile of the inhibitor. Further chemical modifications of 2 b led to the discovery of 4-fluorophenoxy derivative 21 (1-[5-chloro-2-(4-fluorophenoxy)phenyl]-N-hydroxy-1H-1,2,3-triazole-4-carboxamide), a nanomolar smHDAC8 inhibitor (IC50 =0.5 µM), exceeding the smHDAC8 inhibitory activity of 2 b and SAHA (vorinostat), while exhibiting an improved selectivity profile over the investigated human HDACs. Collectively, this study reveals specific interactions between smHDAC8 and the synthesized triazole-based inhibitors and demonstrates that these small molecules represent promising lead structures, which could be further developed in the search for novel drugs for the treatment of schistosomiasis.


Subject(s)
Drug Design , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Schistosoma mansoni/enzymology , Schistosomiasis/drug therapy , Triazoles/pharmacology , Animals , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylase Inhibitors/chemistry , Humans , Models, Molecular , Molecular Structure , Repressor Proteins/antagonists & inhibitors , Repressor Proteins/metabolism , Schistosomiasis/metabolism , Triazoles/chemical synthesis , Triazoles/chemistry
5.
Plos Negl Trop Dis, v. 14, n. 7, e0008332, jul. 2020
Article in English | Sec. Est. Saúde SP, SESSP-IBPROD, Sec. Est. Saúde SP | ID: bud-3085

ABSTRACT

Treatment and control of schistosomiasis still rely on only one effective drug, praziquantel (PZQ) and, due to mass treatment, the increasing risk of selecting for schistosome strains that are resistant to PZQ has alerted investigators to the urgent need to develop novel therapeutic strategies. The histone-modifying enzymes (HMEs) represent promising targets for the development of epigenetic drugs against Schistosoma mansoni. In the present study, we targeted the S. mansoni lysine-specific demethylase 1 (SmLSD1), a transcriptional corepressor, using a novel and selective synthetic inhibitor, MC3935, which was used to treat schistosomula and adult worms in vitro. By using cell viability assays and optical and electron microscopy, we showed that treatment with MC3935 affected parasite motility, egg-laying, tegument, and cellular organelle structures, culminating in the death of schistosomula and adult worms. In silico molecular modeling and docking analysis suggested that MC3935 binds to the catalytic pocket of SmLSD1. Western blot analysis revealed that MC3935 inhibited SmLSD1 demethylation activity of H3K4me1/2. Knockdown of SmLSD1 by RNAi recapitulated MC3935 phenotypes in adult worms. RNA-Seq analysis of MC3935-treated parasites revealed significant differences in gene expression related to critical biological processes. Collectively, our findings show that SmLSD1 is a promising drug target for the treatment of schistosomiasis and strongly support the further development and in vivo testing of selective schistosome LSD1 inhibitors.

6.
J Med Chem ; 62(19): 8733-8759, 2019 10 10.
Article in English | MEDLINE | ID: mdl-31496251

ABSTRACT

The only drug currently available for treatment of the neglected disease Schistosomiasis is Praziquantel, and the possible emergence of resistance makes research on novel therapeutic agents necessary and urgent. To this end, the targeting of Schistosoma mansoni epigenetic enzymes, which regulate the parasitic life cycle, emerged as a promising approach. Due to the strong effects of human sirtuin inhibitors on parasite survival and reproduction, Schistosoma sirtuins were postulated as potential therapeutic targets. In vitro testing of synthetic substrates of S. mansoni sirtuin 2 (SmSirt2) and kinetic experiments on a myristoylated peptide demonstrated lysine long-chain deacylation as an intrinsic SmSirt2 activity in addition to its known deacetylase activity for the first time. Focused in vitro screening of the GSK Kinetobox library and structure-activity relationships of identified hits led to the first SmSirt2 inhibitors with activity in the low micromolar range. Several SmSirt2 inhibitors showed potency against both larval schistosomes (viability) and adult worms (pairing, egg laying) in culture without general toxicity to human cancer cells.


Subject(s)
Helminth Proteins/antagonists & inhibitors , Schistosoma mansoni/metabolism , Sirtuin 2/antagonists & inhibitors , Animals , Helminth Proteins/metabolism , Humans , Kinetics , Larva/drug effects , Larva/metabolism , Lysine/chemistry , Niacinamide/chemistry , Niacinamide/metabolism , Niacinamide/pharmacology , Niacinamide/therapeutic use , Oxadiazoles/chemistry , Oxadiazoles/metabolism , Oxadiazoles/pharmacology , Oxadiazoles/therapeutic use , Peptides/chemistry , Peptides/metabolism , Peptides/pharmacology , Peptides/therapeutic use , Pyrimidines/chemistry , Pyrimidines/metabolism , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Schistosoma mansoni/growth & development , Schistosomiasis/drug therapy , Sirtuin 2/metabolism , Structure-Activity Relationship , Substrate Specificity
7.
J Med Chem ; 61(22): 10000-10016, 2018 11 21.
Article in English | MEDLINE | ID: mdl-30347148

ABSTRACT

Metal-dependent histone deacetylases (HDACs) are key epigenetic regulators that represent promising therapeutic targets for the treatment of numerous human diseases. Yet the currently FDA-approved HDAC inhibitors nonspecifically target at least several of the 11 structurally similar but functionally different HDAC isozymes, which hampers their broad usage in clinical settings. Selective inhibitors targeting single HDAC isozymes are being developed, but precise understanding in molecular terms of their selectivity remains sparse. Here, we show that HDAC8-selective inhibitors adopt a L-shaped conformation required for their binding to a HDAC8-specific pocket formed by HDAC8 catalytic tyrosine and HDAC8 L1 and L6 loops. In other HDAC isozymes, a L1-L6 lock sterically prevents L-shaped inhibitor binding. Shielding of the HDAC8-specific pocket by protein engineering decreases potency of HDAC8-selective inhibitors and affects catalytic activity. Collectively, our results unravel key HDAC8 active site structural and functional determinants important for the design of next-generation chemical probes and epigenetic drugs.


Subject(s)
Catalytic Domain , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/chemistry , Repressor Proteins/antagonists & inhibitors , Repressor Proteins/chemistry , Amino Acid Sequence , Histone Deacetylase Inhibitors/chemistry , Histone Deacetylase Inhibitors/metabolism , Histone Deacetylases/metabolism , Humans , Hydroxamic Acids/chemistry , Hydroxamic Acids/metabolism , Hydroxamic Acids/pharmacology , Indoles/chemistry , Indoles/metabolism , Indoles/pharmacology , Molecular Dynamics Simulation , Repressor Proteins/metabolism , Structure-Activity Relationship , Substrate Specificity , Triazoles/chemistry , Triazoles/metabolism , Triazoles/pharmacology
8.
ChemMedChem ; 13(15): 1517-1529, 2018 08 10.
Article in English | MEDLINE | ID: mdl-29806110

ABSTRACT

Schistosomiasis is a neglected parasitic disease that affects more than 265 million people worldwide and for which the control strategy relies on mass treatment with only one drug: praziquantel. Based on the 3-chlorobenzothiophene-2-hydroxamic acid J1075, a series of hydroxamic acids with different scaffolds were prepared as potential inhibitors of Schistosoma mansoni histone deacetylase 8 (SmHDAC8). The crystal structures of SmHDAC8 with four inhibitors provided insight into the binding mode and orientation of molecules in the binding pocket as well as the orientation of its flexible amino acid residues. The compounds were evaluated in screens for inhibitory activity against schistosome and human HDACs. The most promising compounds were further investigated for their activity toward the major human HDAC isotypes. The most potent inhibitors were additionally screened for lethality against the schistosome larval stage using a fluorescence-based assay. Two of the compounds showed significant, dose-dependent killing of the schistosome larvae and markedly impaired egg laying of adult worm pairs maintained in culture.


Subject(s)
Cinnamates/chemistry , Cinnamates/pharmacology , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/drug effects , Schistosoma mansoni/enzymology , Schistosomiasis/drug therapy , Animals , Cinnamates/chemical synthesis , Cinnamates/therapeutic use , Crystallization , Crystallography, X-Ray , Histone Deacetylases/chemistry , In Vitro Techniques , Molecular Docking Simulation , Protein Conformation , Structure-Activity Relationship
9.
Molecules ; 23(3)2018 Mar 02.
Article in English | MEDLINE | ID: mdl-29498707

ABSTRACT

A promising means in the search of new small molecules for the treatment of schistosomiasis (amongst other parasitic ailments) is by targeting the parasitic epigenome. In the present study, a docking based virtual screening procedure using the crystal structure of histone deacetylase 8 from Schistosoma mansoni (smHDAC8) was designed. From the developed screening protocol, we were able to identify eight novel N-(2,5-dioxopyrrolidin-3-yl)-n-alkylhydroxamate derivatives as smHDAC8 inhibitors with IC50 values ranging from 4.4-20.3 µM against smHDAC8. These newly identified inhibitors were further tested against human histone deacetylases (hsHDAC1, 6 and 8), and were found also to be exerting interesting activity against them. In silico prediction of the docking pose of the compounds was confirmed by the resolved crystal structure of one of the identified hits. This confirmed these compounds were able to chelate the catalytic zinc ion in a bidentate fashion, whilst showing an inverted binding mode of the hydroxamate group when compared to the reported smHDAC8/hydroxamates crystal structures. Therefore, they can be considered as new potential scaffold for the development of new smHDAC8 inhibitors by further investigation of their structure-activity relationship.


Subject(s)
Anthelmintics/chemical synthesis , Chelating Agents/chemical synthesis , Helminth Proteins/antagonists & inhibitors , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylases/chemistry , Hydroxamic Acids/chemical synthesis , Pyrrolidines/chemical synthesis , Schistosoma mansoni/drug effects , Animals , Anthelmintics/pharmacology , Apoptosis/drug effects , Binding Sites , Chelating Agents/pharmacology , Crystallography, X-Ray , Gene Expression , Helminth Proteins/chemistry , Helminth Proteins/genetics , Helminth Proteins/metabolism , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/genetics , Histone Deacetylases/metabolism , Hydroxamic Acids/pharmacology , Molecular Docking Simulation , Protein Binding , Protein Interaction Domains and Motifs , Protein Structure, Secondary , Pyrrolidines/pharmacology , Schistosoma mansoni/enzymology , Schistosoma mansoni/genetics , Schistosoma mansoni/growth & development , Structure-Activity Relationship , Zinc/chemistry , Zinc/metabolism
10.
PLoS Negl Trop Dis ; 11(11): e0006089, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29155817

ABSTRACT

BACKGROUND: Histone deacetylase 8 from Schistosoma mansoni (SmHDAC8) is essential to parasite growth and development within the mammalian host and is under investigation as a target for the development of selective inhibitors as novel schistosomicidal drugs. Although some protein substrates and protein partners of human HDAC8 have been characterized, notably indicating a role in the function of the cohesin complex, nothing is known of the partners and biological function of SmHDAC8. METHODOLOGY/PRINCIPAL FINDINGS: We therefore employed two strategies to characterize the SmHDAC8 interactome. We first used SmHDAC8 as a bait protein in yeast two-hybrid (Y2H) screening of an S. mansoni cDNA library. This allowed the identification of 49 different sequences encoding proteins. We next performed co-immunoprecipitation (Co-IP) experiments on parasite extracts with an anti-SmHDAC8 antibody. Mass spectrometry (MS) analysis allowed the identification of 160 different proteins. CONCLUSIONS/SIGNIFICANCE: SmHDAC8 partners are involved in about 40 different processes, included expected functions such as the cohesin complex, cytoskeleton organization, transcriptional and translational regulation, metabolism, DNA repair, the cell cycle, protein dephosphorylation, proteolysis, protein transport, but also some proteasome and ribosome components were detected. Our results show that SmHDAC8 is a versatile deacetylase, potentially involved in both cytosolic and nuclear processes.


Subject(s)
Helminth Proteins/metabolism , Histone Deacetylases/metabolism , Schistosoma mansoni/enzymology , Animals , Helminth Proteins/genetics , Histone Deacetylases/genetics , Humans , Immunoprecipitation , Protein Binding , Protein Interaction Maps , Schistosoma mansoni/genetics , Schistosoma mansoni/metabolism , Two-Hybrid System Techniques
11.
Arch Pharm (Weinheim) ; 350(8)2017 Aug.
Article in English | MEDLINE | ID: mdl-28639720

ABSTRACT

Schistosoma mansoni histone deacetylase 8 (SmHDAC8) has been recently identified as a new potential target for the treatment of schistosomiasis. A series of newly designed and synthesized alkoxyamide-based and hydrazide-based HDAC inhibitors were tested for inhibitory activity against SmHDAC8 and human HDACs 1, 6, and 8. The front runner compounds showed submicromolar activity against SmHDAC8 and modest preference for SmHDAC8 over its human orthologue hHDAC8. Docking studies provided insights into the putative binding mode in SmHDAC8 and allowed rationalization of the observed selectivity profile.


Subject(s)
Histone Deacetylase Inhibitors/pharmacology , Phthalic Acids/pharmacology , Repressor Proteins/antagonists & inhibitors , Schistosomicides/pharmacology , Animals , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylase Inhibitors/chemistry , Histone Deacetylases , Humans , Molecular Docking Simulation , Phthalic Acids/chemical synthesis , Phthalic Acids/chemistry , Schistosoma mansoni/enzymology , Schistosomicides/chemical synthesis , Schistosomicides/chemistry , Species Specificity
12.
Int J Parasitol Drugs Drug Resist ; 7(1): 42-50, 2017 04.
Article in English | MEDLINE | ID: mdl-28107750

ABSTRACT

Malaria, schistosomiasis and leishmaniases are among the most prevalent tropical parasitic diseases and each requires new innovative treatments. Targeting essential parasite pathways, such as those that regulate gene expression and cell cycle progression, is a key strategy for discovering new drug leads. In this study, four clinically approved anti-cancer drugs (Vorinostat, Belinostat, Panobinostat and Romidepsin) that target histone/lysine deacetylase enzymes were examined for in vitro activity against Plasmodium knowlesi, Schistosoma mansoni, Leishmania amazonensis and L. donovani parasites and two for in vivo activity in a mouse malaria model. All four compounds were potent inhibitors of P. knowlesi malaria parasites (IC50 9-370 nM), with belinostat, panobinostat and vorinostat having 8-45 fold selectivity for the parasite over human neonatal foreskin fibroblast (NFF) or human embryonic kidney (HEK 293) cells, while romidepsin was not selective. Each of the HDAC inhibitor drugs caused hyperacetylation of P. knowlesi histone H4. None of the drugs was active against Leishmania amastigote or promastigote parasites (IC50 > 20 µM) or S. mansoni schistosomula (IC50 > 10 µM), however romidepsin inhibited S. mansoni adult worm parings and egg production (IC50 ∼10 µM). Modest in vivo activity was observed in P. berghei infected mice dosed orally with vorinostat or panobinostat (25 mg/kg twice daily for four days), with a significant reduction in parasitemia observed on days 4-7 and 4-10 after infection (P < 0.05), respectively.


Subject(s)
Histone Deacetylase Inhibitors/pharmacology , Leishmania/drug effects , Plasmodium knowlesi/drug effects , Schistosoma mansoni/drug effects , Acetylation , Administration, Oral , Animals , Depsipeptides/pharmacology , HEK293 Cells , Histone Deacetylase Inhibitors/administration & dosage , Histone Deacetylase Inhibitors/therapeutic use , Histone Deacetylases/metabolism , Histones/metabolism , Humans , Hydroxamic Acids/administration & dosage , Hydroxamic Acids/pharmacology , Hydroxamic Acids/therapeutic use , Indoles/administration & dosage , Indoles/pharmacology , Indoles/therapeutic use , Inhibitory Concentration 50 , Leishmania/growth & development , Life Cycle Stages/drug effects , Malaria/drug therapy , Malaria/parasitology , Mice , Panobinostat , Parasitemia/drug therapy , Plasmodium berghei/drug effects , Plasmodium knowlesi/growth & development , Schistosoma mansoni/growth & development , Sulfonamides/pharmacology , Vorinostat
13.
J Med Chem ; 59(6): 2423-35, 2016 Mar 24.
Article in English | MEDLINE | ID: mdl-26937828

ABSTRACT

Schistosomiasis is a major neglected parasitic disease that affects more than 265 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. In this study, a series of new benzohydroxamates were prepared as potent inhibitors of Schistosoma mansoni histone deacetylase 8 (smHDAC8). Crystallographic analysis provided insights into the inhibition mode of smHDAC8 activity by these 3-amidobenzohydroxamates. The newly designed inhibitors were evaluated in screens for enzyme inhibitory activity against schistosome and human HDACs. Twenty-seven compounds were found to be active in the nanomolar range, and some of them showed selectivity toward smHDAC8 over the major human HDACs (1 and 6). The active benzohydroxamates were additionally screened for lethality against the schistosome larval stage using a fluorescence-based assay. Four of these showed significant dose-dependent killing of the schistosome larvae and markedly impaired egg laying of adult worm pairs maintained in culture.


Subject(s)
Helminth Proteins/drug effects , Histone Deacetylases/drug effects , Schistosoma mansoni/drug effects , Schistosomicides/chemical synthesis , Schistosomicides/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Delivery Systems , Humans , Larva , Models, Molecular , Schistosoma mansoni/genetics , Schistosomiasis mansoni/drug therapy , Structure-Activity Relationship , Substrate Specificity , X-Ray Diffraction
14.
BMC Genomics ; 16: 980, 2015 Nov 19.
Article in English | MEDLINE | ID: mdl-26584526

ABSTRACT

BACKGROUND: The trematode parasite, Schistosoma mansoni, has evolved to switch from oxidative phosphorylation to glycolysis in the presence of glucose immediately after invading the human host. This metabolic switch is dependent on extracellular glucose concentration. Four glucose transporters are encoded in the genome of S. mansoni, however, only two were shown to facilitate glucose diffusion. RESULTS: By modeling the phase of human host infection, we showed that transporter transcript expression profiles of recently transformed schistosomula have two opposing responses to increased glucose concentrations. Concurring with the transcription profiles, our phylogenetic analyses revealed that S. mansoni glucose transporters belong to two separate clusters, one associated with class I glucose transporters from vertebrates and insects, and the other specific to parasitic Platyhelminthes. To study the evolutionary paths of both groups and their functional implications, we determined evolutionary rates, relative divergence times, genomic organization and performed structural analyses with the protein sequences. We finally used the modelled structures of the S. mansoni glucose transporters to biophysically (i) analyze the dynamics of key residues during glucose binding, (ii) test glucose stability within the active site, and (iii) demonstrate glucose diffusion. The two S. mansoni Platyhelminthes-specific glucose transporters, which seem to be younger than the other two, exhibit slower rates of molecular evolution, are encoded by intron-poor genes, and transport glucose. Interestingly, our molecular dynamic analyses suggest that S. mansoni class I glucose transporters are not able to transport glucose. CONCLUSIONS: The glucose transporter family in S. mansoni exhibit different evolutionary histories. Our results suggested that S. mansoni class I glucose transporters lost their capacity to transport glucose and that this function evolved independently in the Platyhelminthes-specific glucose transporters. Finally, taking into account the differences in the dynamics of glucose transport of the Platyhelminthes-specific transporters of S. mansoni compared to that of humans, we conclude that S. mansoni glucose transporters may be targets for rationally designed drugs against schistosomiasis.


Subject(s)
Evolution, Molecular , Glucose Transport Proteins, Facilitative/metabolism , Schistosoma mansoni/genetics , Schistosoma mansoni/metabolism , Algorithms , Amino Acid Sequence , Animals , Biological Transport , Glucose/metabolism , Glucose Transport Proteins, Facilitative/chemistry , Glucose Transport Proteins, Facilitative/genetics , Host-Parasite Interactions , Humans , Introns/genetics , Larva/genetics , Larva/metabolism , Models, Biological , Models, Molecular , Molecular Sequence Data , Phylogeny , Protein Structure, Tertiary , Schistosoma mansoni/physiology , Transcription, Genetic
15.
Future Med Chem ; 7(6): 765-82, 2015.
Article in English | MEDLINE | ID: mdl-25996069

ABSTRACT

The sirtuins form a superfamily of evolutionarily conserved NAD(+)-dependent protein N-ϵ-acyl-lysine (AcK) deacylases with roles in a variety of key cellular processes. Sirtuins have a broadly conserved overall structure with a catalytic site formed by a hydrophobic channel between the NAD(+)-binding Rossmann fold domain and a smaller Zn(2+)-binding domain. Schistosomes express five members of the sirtuin family and generic sirtuin inhibitors induce apoptosis and death in schistosome larvae, the disruption of adult worm pairs, inhibition of egg laying and damage to the male and female worm reproductive systems. Sirtuins in schistosomes and other parasitic flatworms present structural differences from their human orthologues that should allow the development of selective inhibitors that can be developed as drug leads.


Subject(s)
Anthelmintics/pharmacology , Drug Discovery/methods , Helminth Proteins/antagonists & inhibitors , Schistosoma/drug effects , Schistosomiasis/drug therapy , Sirtuins/antagonists & inhibitors , Amino Acid Sequence , Animals , Anthelmintics/chemistry , Helminth Proteins/chemistry , Helminth Proteins/metabolism , Humans , Models, Molecular , Molecular Sequence Data , Molecular Targeted Therapy/methods , Schistosoma/chemistry , Schistosoma/metabolism , Schistosomiasis/parasitology , Sequence Alignment , Sirtuins/chemistry , Sirtuins/metabolism
16.
J Biomol Screen ; 20(1): 112-21, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25325257

ABSTRACT

Sirtuins are NAD(+)-dependent histone deacetylases (HDACs) that cleave off acetyl but also other acyl groups from the ϵ-amino group of lysines in histones and other substrate proteins. Five sirtuin isoforms are encoded in the genome of the parasitic pathogen Schistosoma mansoni. During its life cycle, S. mansoni undergoes drastic changes in phenotype that are associated with epigenetic modifications. Previous work showed strong effects of hSirt2 inhibitors on both worm life span and reproduction. Thus, we postulate smSirt2 as a new antiparasite target. We report both the optimization of a homogeneous fluorescence-based assay and the development of a new heterogeneous fluorescence-based assay to determine smSirt2 activity. The homogeneous assay uses a coumarin-labeled acetyl lysine derivative, and the heterogeneous version is using a biotinylated and fluorescence-labeled oligopeptide. Magnetic streptavidin-coated beads allow higher substrate loading per well than streptavidin-coated microtiter plates and make it possible to screen for inhibitors of either smSirt2 or its human isoform (hSirt2) for selectivity studies. We also present hits from a pilot screen with inhibitors showing an IC50 lower than 50 µM. Binding of the hits to their targets is rationalized by docking studies using a homology model of smSirt2.


Subject(s)
Fluorometry/methods , Schistosoma mansoni/enzymology , Sirtuin 2/metabolism , Animals , Binding Sites , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Epigenesis, Genetic/drug effects , Humans , Inhibitory Concentration 50 , Models, Molecular , Molecular Conformation , Niacinamide/chemistry , Niacinamide/pharmacology , Protein Binding , Schistosoma mansoni/drug effects , Schistosoma mansoni/genetics , Sirtuin 2/antagonists & inhibitors , Sirtuin 2/genetics , Structure-Activity Relationship , Tyrphostins/chemistry , Tyrphostins/pharmacology
17.
Int J Parasitol Drugs Drug Resist ; 4(3): 256-66, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25516836

ABSTRACT

Protein kinases (PKs) are one of the largest protein families in most eukaryotic organisms. These enzymes are involved in the control of cell proliferation, differentiation and metabolism and a large number of the anticancer drugs currently used are directed against PKs. The structure and function of PKs are well conserved throughout evolution. In schistosome parasites, PKs were shown to be involved in essential functions at every stage of the parasite life cycle, making these enzymes promising anti-parasite drug targets. In this study, we tested a panel of commercial inhibitors for various PKs and analyzed their effects on pairing and egg production by schistosomes as well as their toxicity towards schistosomula larvae. Results obtained confirmed the deleterious effect of PK targeting on Schistosoma mansoni physiology and the important function of different tyrosine and serine/threonine kinases in the biology and reproduction of this parasite. They also indicated for the first time that the Protein kinase B (also called Akt) which is a major downstream target of many receptor tyrosine kinases and a central player at the crossroads of signal transduction pathways activated in response to growth factors and insulin, can constitute a novel target for anti-schistosome chemotherapy. Structural and functional studies have shown that SmAkt is a conserved kinase and that its activity can be inhibited by commercially available Akt inhibitors. In treated adult worms, Akt/PKB kinase pathway inhibitors induced profound alterations in pairing and egg laying and they also greatly affected the viability of schistosomula larvae.

18.
Front Genet ; 5: 317, 2014.
Article in English | MEDLINE | ID: mdl-25309576

ABSTRACT

The discovery of the epigenetic regulation of gene expression has revolutionized both our understanding of how genomes function and approaches to the therapy of numerous pathologies. Schistosomes are metazoan parasites and as such utilize most, if not all the epigenetic mechanisms in play in their vertebrate hosts: histone variants, histone tail modifications, non-coding RNA and, perhaps, DNA methylation. Moreover, we are acquiring an increasing understanding of the ways in which these mechanisms come into play during the complex schistosome developmental program. In turn, interest in the actors involved in epigenetic mechanisms, particularly the enzymes that carry out epigenetic modifications of histones or nucleic acid, as therapeutic targets has been stimulated by the finding that their inhibitors exert profound effects, not only on survival, but also on the reproductive function of Schistosoma mansoni. Here, we review our current knowledge, and what we can infer, about the role of epigenetic mechanisms in schistosome development, differentiation and survival. We will consider which epigenetic actors can be targeted for drug discovery and what strategies can be employed to develop potent, selective inhibitors as drugs to cure schistosomiasis.

19.
PLoS Pathog ; 10(5): e1004116, 2014 May.
Article in English | MEDLINE | ID: mdl-24809504

ABSTRACT

Treatment and control of schistosomiasis relies on the only available drug, praziquantel, and the search for alternative chemotherapeutic agents is therefore urgent. Egg production is required for the transmission and immunopathology of schistosomiasis and females of S. mansoni lay 300 eggs daily. A large fraction of the total mRNA in the mature female worm encodes one eggshell protein, Smp14. We report that the nuclear receptors SmRXR1 and SmNR1 regulate Smp14 transcription through the recruitment of two histone acetyltransferases (HATs), SmGCN5 and SmCBP1. The treatment of HEK293 cells with histone deacetylase (HDAC) inhibitors (NaB or TSA) produced an 8-fold activation of the SmRXR1/SmNR1-mediated Smp14 promoter activity. Incubation with synthetic HAT inhibitors, including PU139, significantly impaired the Smp14 promoter activity in these cells. Worm pairs cultivated in the presence of PU139 exhibited limited expression of Smp14 mRNA and protein. ChIP analysis demonstrated chromatin condensation at the Smp14 promoter site in worms treated with PU139. ChIP also revealed the presence of H3K27me3 and the absence of RNA Pol II at the Smp14 promoter region in the PU139-treated worms. Most significantly, the PU139-mediated inhibition of Smp14 expression resulted in a significant number of abnormal eggs as well as defective eggs within the ootype. In addition, scanning electron microscopy revealed structural defects and unformed eggshells, and vitelline cell leakage was apparent. The dsRNAi-targeting of SmGCN5 or SmCBP1 significantly decreased Smp14 transcription and protein synthesis, which compromised the reproductive system of mature female worms, egg-laying and egg morphology. Our data strongly suggest that the inhibition of Smp14 expression targeting SmGCN5 and/or SmCBP1 represents a novel and effective strategy to control S. mansoni egg development.


Subject(s)
Anthelmintics/therapeutic use , Egg Proteins/genetics , Epigenesis, Genetic/physiology , Oviparity/genetics , Schistosoma mansoni/physiology , Schistosomiasis/prevention & control , Schistosomiasis/transmission , Animals , Egg Proteins/metabolism , Female , Gene Expression Regulation, Developmental/drug effects , HEK293 Cells , Helminth Proteins/genetics , Helminth Proteins/metabolism , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylase Inhibitors/therapeutic use , Humans , Male , Molecular Targeted Therapy/methods , Schistosoma mansoni/genetics , Schistosoma mansoni/growth & development
20.
J Mol Biol ; 426(20): 3442-53, 2014 Oct 09.
Article in English | MEDLINE | ID: mdl-24657767

ABSTRACT

Schistosomiasis, caused by the parasitic flatworm Schistosoma mansoni and related species, is a tropical disease that affects over 200 million people worldwide. A new approach for targeting eukaryotic parasites is to tackle their dynamic epigenetic machinery that is necessary for the extensive phenotypic changes during the life cycle of the parasite. Recently, we identified S. mansoni histone deacetylase 8 (smHDAC8) as a potential target for antiparasitic therapy. Here, we present results on the investigations of a focused set of HDAC (histone deacetylase) inhibitors on smHDAC8. Besides several active hydroxamates, we identified a thiol-based inhibitor that inhibited smHDAC8 activity in the micromolar range with unexpected selectivity over the human isotype, which has not been observed so far. The crystal structure of smHDAC8 complexed with the thiol derivative revealed that the inhibitor is accommodated in the catalytic pocket, where it interacts with both the catalytic zinc ion and the essential catalytic tyrosine (Y341) residue via its mercaptoacetamide warhead. To our knowledge, this is the first complex crystal structure of any HDAC inhibited by a mercaptoacetamide inhibitor, and therefore, this finding offers a rationale for further improvement. Finally, an ester prodrug of the thiol HDAC inhibitor exhibited antiparasitic activity on cultured schistosomes in a dose-dependent manner.


Subject(s)
Antiparasitic Agents/chemistry , Helminth Proteins/chemistry , Histone Deacetylases/chemistry , Schistosoma mansoni/enzymology , Thioacetamide/chemistry , Animals , Antiparasitic Agents/metabolism , Antiparasitic Agents/pharmacology , Apoptosis/drug effects , Biocatalysis/drug effects , Crystallography, X-Ray , Helminth Proteins/antagonists & inhibitors , Helminth Proteins/metabolism , Histone Deacetylase Inhibitors/chemistry , Histone Deacetylase Inhibitors/metabolism , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Humans , Hydroxamic Acids/chemistry , Hydroxamic Acids/metabolism , Hydroxamic Acids/pharmacology , Inhibitory Concentration 50 , Models, Molecular , Molecular Structure , Protein Binding , Protein Structure, Tertiary , Schistosoma mansoni/drug effects , Schistosoma mansoni/physiology , Schistosomiasis mansoni/parasitology , Thioacetamide/metabolism , Thioacetamide/pharmacology , Vorinostat
SELECTION OF CITATIONS
SEARCH DETAIL
...